FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4375955564> ?p ?o ?g. }

• W4375955564 endingPage "e2310223" @default.
• W4375955564 startingPage "e2310223" @default.
• W4375955564 abstract "Importance To date, no psychopharmacologic treatment has been found to be uniformly effective in veterans with posttraumatic stress disorder (PTSD); novel targets and approaches are needed to treat this disabling disorder. Objective To examine whether treatment with the glucocorticoid receptor antagonist mifepristone yields a signal for clinical efficacy in male veterans with PTSD. Design, Setting, and Participants This phase 2a, double-blind, parallel-group randomized clinical trial was conducted from November 19, 2012 (accrual started), through November 16, 2016 (final follow-up), within the US Department of Veterans Affairs. Participants were male veterans with chronic PTSD and a screening Clinician-Administered PTSD Scale score of 50 or higher. A total of 181 veterans consented to participation. Statistical analysis was conducted between August 2014 and May 2017. Interventions Participants were randomized in a 1:1 ratio to mifepristone (600 mg) or matched placebo taken orally for 7 days. Main Outcomes and Measures The clinical outcome was whether a veteran achieved a clinical response status (a reduction of ≥30% of total Clinician-Administered PTSD Scale score from baseline) at 4- and 12-week follow-up. On the basis of a binary statistical selection rule, a difference in the proportion of treatment vs control group responders of 15% would be a clinically relevant difference. Self-report measures of PTSD and associated symptoms were also obtained. Neuroendocrine outcomes and plasma levels of mifepristone were measured. Safety was assessed throughout the study. The primary analysis was based on a multiple imputation technique to address missing outcome data; thus, some participant numbers may not appear as whole numbers. Results A total of 81 veterans were enrolled and randomized. Excluding 1 participant randomized in error, 80 were included in the modified intention-to-treat analysis (41 randomized to mifepristone and 39 to placebo). The mean (SD) age was 43.1 (13.7) years. A total of 15.6 (38.1%) in the mifepristone group and 12.1 (31.1%) in the placebo group were clinical responders at 4 weeks in the analysis using the multiple imputation technique. The group difference in the proportion of clinical responders (7.0%) was less than the predefined margin of 15% indicating signal for clinical efficacy. In an exploratory analysis, the difference in response to mifepristone vs placebo in the subgroup with no lifetime history of traumatic brain injury (TBI) (7.0 [50.0%] vs 3.0 [27.3%]; difference, 22.7%) exceeded the efficacy margin at 4 weeks and was sustained at 12 weeks. In contrast, in veterans with PTSD and lifetime TBI, the response rate to mifepristone was lower than placebo at 12 weeks (7.4 [27.4%] vs 13.5 [48.3%]; difference, −20.9%). Conclusions and Relevance This study did not detect a signal for efficacy for mifepristone at 600 mg/d for 1 week in male veterans with chronic PTSD. Thus, this study does not support a phase 3 trial in this population. Future studies of mifepristone for the treatment of PTSD may be of interest in those without a history of TBI or in samples with a low base rate of lifetime head trauma. Trial Registration ClinicalTrials.gov Identifier: NCT01946685" @default.
• W4375955564 created "2023-05-10" @default.
• W4375955564 creator A5013792936 @default.
• W4375955564 creator A5023466877 @default.
• W4375955564 creator A5025945146 @default.
• W4375955564 creator A5058313382 @default.
• W4375955564 creator A5072627434 @default.
• W4375955564 creator A5078440960 @default.
• W4375955564 creator A5079669862 @default.
• W4375955564 creator A5084562941 @default.
• W4375955564 creator A5085696635 @default.
• W4375955564 creator A5088026153 @default.
• W4375955564 date "2023-05-09" @default.
• W4375955564 modified "2023-10-06" @default.
• W4375955564 title "Efficacy and Safety of Mifepristone in the Treatment of Male US Veterans With Posttraumatic Stress Disorder" @default.
• W4375955564 cites W1623994224 @default.
• W4375955564 cites W1897310022 @default.
• W4375955564 cites W1967122944 @default.
• W4375955564 cites W1983324998 @default.
• W4375955564 cites W1986381796 @default.
• W4375955564 cites W1998996424 @default.
• W4375955564 cites W2008637156 @default.
• W4375955564 cites W2035445406 @default.
• W4375955564 cites W2040626393 @default.
• W4375955564 cites W2060657121 @default.
• W4375955564 cites W2067495470 @default.
• W4375955564 cites W2081535802 @default.
• W4375955564 cites W2090776417 @default.
• W4375955564 cites W2091136922 @default.
• W4375955564 cites W2092916960 @default.
• W4375955564 cites W2093982682 @default.
• W4375955564 cites W2094767740 @default.
• W4375955564 cites W2101187962 @default.
• W4375955564 cites W2107489190 @default.
• W4375955564 cites W2129371541 @default.
• W4375955564 cites W2132539548 @default.
• W4375955564 cites W2148083007 @default.
• W4375955564 cites W2151487996 @default.
• W4375955564 cites W2169828275 @default.
• W4375955564 cites W2401795134 @default.
• W4375955564 cites W2734724603 @default.
• W4375955564 cites W2737966001 @default.
• W4375955564 cites W2789959403 @default.
• W4375955564 cites W2889129864 @default.
• W4375955564 cites W2891631991 @default.
• W4375955564 cites W3157569905 @default.
• W4375955564 cites W4206474475 @default.
• W4375955564 cites W4233507025 @default.
• W4375955564 cites W4239960582 @default.
• W4375955564 cites W4245295585 @default.
• W4375955564 cites W4299905880 @default.
• W4375955564 cites W49144085 @default.
• W4375955564 cites W74340424 @default.
• W4375955564 doi "https://doi.org/10.1001/jamanetworkopen.2023.10223" @default.
• W4375955564 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37159200" @default.
• W4375955564 hasPublicationYear "2023" @default.
• W4375955564 type Work @default.
• W4375955564 citedByCount "1" @default.
• W4375955564 countsByYear W43759555642023 @default.
• W4375955564 crossrefType "journal-article" @default.
• W4375955564 hasAuthorship W4375955564A5013792936 @default.
• W4375955564 hasAuthorship W4375955564A5023466877 @default.
• W4375955564 hasAuthorship W4375955564A5025945146 @default.
• W4375955564 hasAuthorship W4375955564A5058313382 @default.
• W4375955564 hasAuthorship W4375955564A5072627434 @default.
• W4375955564 hasAuthorship W4375955564A5078440960 @default.
• W4375955564 hasAuthorship W4375955564A5079669862 @default.
• W4375955564 hasAuthorship W4375955564A5084562941 @default.
• W4375955564 hasAuthorship W4375955564A5085696635 @default.
• W4375955564 hasAuthorship W4375955564A5088026153 @default.
• W4375955564 hasBestOaLocation W43759555641 @default.
• W4375955564 hasConcept C118552586 @default.
• W4375955564 hasConcept C126322002 @default.
• W4375955564 hasConcept C142724271 @default.
• W4375955564 hasConcept C168563851 @default.
• W4375955564 hasConcept C204787440 @default.
• W4375955564 hasConcept C27081682 @default.
• W4375955564 hasConcept C27415008 @default.
• W4375955564 hasConcept C2775969662 @default.
• W4375955564 hasConcept C2778826759 @default.
• W4375955564 hasConcept C2779234561 @default.
• W4375955564 hasConcept C535046627 @default.
• W4375955564 hasConcept C54355233 @default.
• W4375955564 hasConcept C70410870 @default.
• W4375955564 hasConcept C71924100 @default.
• W4375955564 hasConcept C86803240 @default.
• W4375955564 hasConceptScore W4375955564C118552586 @default.
• W4375955564 hasConceptScore W4375955564C126322002 @default.
• W4375955564 hasConceptScore W4375955564C142724271 @default.
• W4375955564 hasConceptScore W4375955564C168563851 @default.
• W4375955564 hasConceptScore W4375955564C204787440 @default.
• W4375955564 hasConceptScore W4375955564C27081682 @default.
• W4375955564 hasConceptScore W4375955564C27415008 @default.
• W4375955564 hasConceptScore W4375955564C2775969662 @default.
• W4375955564 hasConceptScore W4375955564C2778826759 @default.
• W4375955564 hasConceptScore W4375955564C2779234561 @default.
• W4375955564 hasConceptScore W4375955564C535046627 @default.
• W4375955564 hasConceptScore W4375955564C54355233 @default.

• next